Joshua Jennings
Stock Analyst at TD Cowen
(3.21)
# 1,074
Out of 5,141 analysts
81
Total ratings
45.21%
Success rate
3.77%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $74.58 | +34.08% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $242.49 | +3.10% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $79.78 | +21.58% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $3.93 | +282.17% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $20.22 | -1.09% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $8.16 | +83.82% | 2 | Nov 5, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $85 → $50 | $27.27 | +83.35% | 4 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $73.08 | +14.94% | 2 | Oct 31, 2025 | |
| HUMA Humacyte | Maintains: Buy | $5 → $3.5 | $1.13 | +209.73% | 3 | Aug 12, 2025 | |
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $5.68 | +164.08% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $241.89 | +33.95% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $134.25 | -10.61% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.09 | +4,487.16% | 1 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $98.75 | +20.51% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $38.09 | +57.52% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $80.44 | -0.55% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $3.53 | +1,174.79% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $21.58 | +85.36% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $380.23 | +5.20% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $76.00 | -21.05% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $24.57 | +38.38% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.90 | +160.87% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.87 | +39.90% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $112.21 | +15.85% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.07 | +141.55% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $96.86 | +20.79% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $2.26 | +19,811.50% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $13.01 | -7.76% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $185.39 | +48.34% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $10.05 | +173.63% | 3 | Sep 5, 2018 |
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $74.58
Upside: +34.08%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $242.49
Upside: +3.10%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $79.78
Upside: +21.58%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $3.93
Upside: +282.17%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $20.22
Upside: -1.09%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $8.16
Upside: +83.82%
PROCEPT BioRobotics
Nov 5, 2025
Maintains: Buy
Price Target: $85 → $50
Current: $27.27
Upside: +83.35%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $73.08
Upside: +14.94%
Humacyte
Aug 12, 2025
Maintains: Buy
Price Target: $5 → $3.5
Current: $1.13
Upside: +209.73%
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.68
Upside: +164.08%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $241.89
Upside: +33.95%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $134.25
Upside: -10.61%
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $1.09
Upside: +4,487.16%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $98.75
Upside: +20.51%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $38.09
Upside: +57.52%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $80.44
Upside: -0.55%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $3.53
Upside: +1,174.79%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $21.58
Upside: +85.36%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $380.23
Upside: +5.20%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $76.00
Upside: -21.05%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $24.57
Upside: +38.38%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.90
Upside: +160.87%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.87
Upside: +39.90%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $112.21
Upside: +15.85%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.07
Upside: +141.55%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $96.86
Upside: +20.79%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $2.26
Upside: +19,811.50%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $13.01
Upside: -7.76%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $185.39
Upside: +48.34%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $10.05
Upside: +173.63%